Yung MD - Tourmaline Bio Chief Officer
| TRML Stock | 25.00 0.36 1.42% |
Executive
Yung MD is Chief Officer of Tourmaline Bio
| Age | 48 |
| Address | 27 West 24th Street, New York, NY, United States, 10010 |
| Phone | 646-481-9832 |
| Web | https://www.tourmalinebio.com |
Tourmaline Bio Management Efficiency
The company has return on total asset (ROA) of (0.2382) % which means that it has lost $0.2382 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3182) %, meaning that it created substantial loss on money invested by shareholders. Tourmaline Bio's management efficiency ratios could be used to measure how well Tourmaline Bio manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.21. The value of Return On Capital Employed is expected to slide to -0.23. At this time, Tourmaline Bio's Other Assets are quite stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Leite | Veracyte | 52 | |
| Jaime Mercado | Dominari Holdings | N/A | |
| John Leonard | Vaccinex | 77 | |
| Peter Buhler | Valneva SE ADR | 53 | |
| Kristina Maximenko | Dianthus Therapeutics | N/A | |
| MS MD | DiaMedica Therapeutics | 51 | |
| Matthew McCullough | Dominari Holdings | 38 | |
| Keith Gligorich | Veracyte | N/A | |
| Chris Walsh | Denali Therapeutics | N/A | |
| Tyler Nielsen | Denali Therapeutics | 46 | |
| Jason Keyes | Equillium | 53 | |
| Mark Rowen | Denali Therapeutics | N/A | |
| Donald MBA | Vivani Medical | 65 | |
| Joshua Drumm | Valneva SE ADR | N/A | |
| Dipal Patel | Valneva SE ADR | 49 | |
| Maple MD | Equillium | N/A | |
| Michael Moore | Equillium | N/A | |
| George CPA | Dominari Holdings | 56 | |
| Petra Pesendorfer | Valneva SE ADR | 38 | |
| Hanneke Schuitemaker | Valneva SE ADR | N/A | |
| David Wambeke | DiaMedica Therapeutics | 40 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.24 |
Tourmaline Bio Leadership Team
Elected by the shareholders, the Tourmaline Bio's board of directors comprises two types of representatives: Tourmaline Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tourmaline. The board's role is to monitor Tourmaline Bio's management team and ensure that shareholders' interests are well served. Tourmaline Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tourmaline Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Jones, Chief Officer | ||
| Sandeep MD, CEO CoFounder | ||
| Kimberly Piorkowski, Culture People | ||
| Bradford JD, General Officer | ||
| Dr MBA, Chief Officer | ||
| Emil MD, Senior Research | ||
| Yung MD, Chief Officer | ||
| Gerhard PharmD, Senior Development | ||
| John MD, VP Affairs | ||
| Kristine OD, Medical Ophthalmology | ||
| Dora Rau, Senior Quality | ||
| Ryan Iarrobino, Senior Development | ||
| Famina PharmD, VP Pharmacovigilance | ||
| Don Fitch, Senior Development | ||
| Ryan CPA, Controller Finance |
Tourmaline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tourmaline Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 383.28 M | ||||
| Shares Outstanding | 25.64 M | ||||
| Shares Owned By Insiders | 22.61 % | ||||
| Shares Owned By Institutions | 83.90 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Book | 2.07 X | ||||
| EBITDA | (45.38 M) | ||||
| Net Income | (42.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.49) | Return On Assets (0.24) | Return On Equity (0.32) |
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.